BRD2 and ductal breast carcinoma in situ: The remaining 47.8% had other varying changes in SEMA7A expression across DCIS + IDC progression; for example, some tissues had increased expression between NAT and DCIS with no change between DCIS and IDC, or a decrease in SEMA7A expression from between NAT and DCIS with a larger increase between DCIS and IDC.